Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 10, 2017 06:30 ET | Source: AnaptysBio, Inc.

AnaptysBio Reports Positive Topline Proof-of-Concept Data from Phase 2a Clinical Trial of ANB020 in Atopic Dermatitis

83 Percent of Patients Achieved EASI-50 at Day 29 Following a Single Dose of ANB020EASI-50 was Observed Early and Persisted Through Day 57Management to Host Conference Call Today at 8:30 a.m. EDT SAN...
August 24, 2017 08:00 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces Appointment of J. Anthony Ware, M.D. to Board of Directors

SAN DIEGO, Aug. 24, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...
August 10, 2017 16:30 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces Second Quarter 2017 Financial Results and Provides Pipeline Updates

Enrollment Completed in ANB020 Phase 2a Trial for Atopic Dermatitis Multiple Top-Line Clinical Data Readouts Expected in Second Half of 2017 SAN DIEGO, Aug. 10, 2017 (GLOBE NEWSWIRE) -- ...
August 08, 2017 06:30 ET | Source: AnaptysBio, Inc.

AnaptysBio to Present at Wedbush PacGrow Healthcare Conference

SAN DIEGO, Aug. 08, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...
June 01, 2017 06:30 ET | Source: AnaptysBio, Inc.

AnaptysBio to Participate in Upcoming Investor Conferences

SAN DIEGO, June 01, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...
May 11, 2017 16:30 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces First Quarter 2017 Financial Results and Provides Pipeline Update

SAN DIEGO, May 11, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...
April 06, 2017 08:00 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces First-In-Human Dosing of ANB019

SAN DIEGO, April 06, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...
March 08, 2017 16:30 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces 2016 Operating Results and Pipeline Progress

SAN DIEGO, March 08, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...
March 04, 2017 15:00 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces Data from Scientific Collaboration with the Benaroya Research Institute Presented at the AAAAI 2017 Annual Meeting

SAN DIEGO, March 04, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...
February 13, 2017 08:00 ET | Source: AnaptysBio, Inc.

AnaptysBio to Present Data from ANB020 Program at Two Upcoming Medical Meetings

SAN DIEGO, Feb. 13, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...